Takeda Pharmaceuticals International (TPI) is launching Takeda Peru, a wholly owned subsidiary that will be headquartered in Lima. TPI already has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia, and Ecuador, and it is looking at opportunities to further expand its footprint in the region.
According to IMS Market Prognosis, pharmaceutical sales in those countries totaled $60 billion in 2012 and are expected to grow at a compound annual rate of 12.5% between 2013 and 2017. It is estimated that Peru's GDP totaled $200 billion in 2012 while pharmaceutical sales amounted to $1.5 billion and are expected to continue to grow by 8% during 2013.
Takeda Peru noted that it is building a product portfolio based on the medical needs of the population, focusing on gastroenterology, cardiology, metabolism, oncology, and respiratory diseases. Takeda Peru will initially focus on Zurcal (pantoprazole), Riopan (Magaldrate + Dimeticone), Faktu (Policresulen, Cinchocaine hydrochloride), and its gynecology product, Albothyl (Policresulen), which Takeda repatriated following the Nycomed acquisition.
“We have an established product portfolio … and we look forward to launching our novel medicines into the market,” said Norbert Oppitz, senior vice president, Latin America, at TPI. “This investment further demonstrates our commitment to Latin America and its growth potential.”